Biomarker Changes in Samples From Young Patients With Acute Myeloid Leukemia

Epigenetic Alterations in AML

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01139931

Enrollment

Registered

2010-06-09

Start date

2009-10-31

Completion date

Unknown

Last updated

2016-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukemia

Keywords

childhood acute myeloid leukemia/other myeloid malignancies

Brief summary

RATIONALE: Studying samples of blood or tumor tissue from patients with cancer in the laboratory may help doctors learn about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is studying biomarker changes in samples from young patients with acute myeloid leukemia.

Detailed description

OBJECTIVES: * Map key histone modifications and cytosine methylation in leukemia cell lines with defined oncogenic mutations. * Acquire genome-wide maps of key histone modifications and cytosine methylation for primary leukemia in samples from patients with acute myeloid leukemia (AML). * Investigate functional relationships between genetic and epigenetic landscapes in AML. OUTLINE: Archived samples are analyzed in vivo and in vitro (cell line) for histone modification and cytosine methylation. Genome-wide locations of 5 histone modifications are analyzed using chip-Seq, as well as DNA methylation analysis at nucleotide-resolution by high-throughput bisulfite sequencing. These epigenetic data are correlated with genomic data (sequence analysis, expression array, SNP array).

Interventions

GENETICDNA methylation analysis

GENETICgene expression analysis

GENETICmicroarray analysis

GENETICpolymorphism analysis

OTHERlaboratory biomarker analysis

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 17 Years

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Diagnosis of acute myeloid leukemia * Primary leukemia samples from the Children Oncology Group (COG) bank with sufficient number of cells (500,000-1 million cells) with \> 80% of leukemia blasts PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Design outcomes

Primary

Measure	Time frame
Relationships between genetic and epigenetic landscapes in AML	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026